You just read:

Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy

News provided by

Audentes Therapeutics, Inc.

Apr 03, 2017, 08:00 ET